Ethics and ego dissolution: the case of psilocybin

Area of Science:

• Psychiatry
• Neuroscience
• Pharmacology

Background:

• Psychedelics, once restricted, are now showing therapeutic potential for mental and substance use disorders.
• Recent trials indicate novel benefits, with unique subjective experiences differentiating them from conventional treatments.

Purpose of the Study:

• To examine the novel risks associated with psychedelic experiences.
• To propose an enhanced informed consent process for psychedelic-assisted therapies.
• To discuss ethical considerations for integrating psychedelics into mainstream clinical practice.

Main Methods:

• Review of early-phase clinical trials on psychedelics.
• Focus on psilocybin as a case study.
• Analysis of the unique features of the psychedelic experience and associated risks.

Main Results:

• Psychedelic experiences, such as ego dissolution and profound insights, differ significantly from other treatments.
• These experiences can lead to lasting personality and worldview changes.
• Novel risks necessitate a more comprehensive informed consent process.

Conclusions:

• An enhanced informed consent process is essential for psychedelic psychiatry.
• Key issues and discussion prompts for consent were identified.
• Ethical considerations must be addressed as psychedelic therapies move toward wider clinical adoption.